Key Takeaways
- Flat quarter, mixed drivers: Revenue grew just 2% YoY as a 124% surge in exports and 42% growth in trade generics were offset by a 10% decline in the core CDMO business.
- CDMO weakness is lumpy, not structural: The 10% YoY CDMO decline reflects a quarter where the IPM growth spike came from anti-infectives (a category Windlas does not play in), new launches were postponed, and some MNCs deferred inventory pickup. Management urges looking at YTD trends, not quarterly swings.
- Trade generics is the growth engine with a long runway: The business has grown at 40%+ historically and management believes 20–25%+ is sustainable long-term, driven by a distribution model that reaches 5.5 lakh villages and kasbahs that branded generics cannot serve.
- Margins improved despite the top-line drag: EBITDA margin expanded to 11.7% from 11.1% YoY, helped by a 219 bps gross margin improvement and decreasing input price volatility.
- What to watch next quarter: Whether the Sacubitril Valsartan launch and new DCGI-approved products can re-energize CDMO growth, and whether the injectable facility capex stays on track for a March 31 completion.
CDMO: The Core Business in a Soft Patch
- The flat growth unpacked: CDMO revenue was flat because the Indian pharma market's Q3 growth was driven by anti-infectives and antibiotics, a therapeutic area where Windlas has no presence. The underlying IPM volume growth excluding that spike was only 2–3%, and Windlas also faced postponed new launches and some multinationals not picking up inventory toward December.
- Quarterly lumpiness is normal at this scale: In Q2, when IPM volume growth was 3–5%, Windlas delivered 15% CDMO growth. Management argues the ₹400 crore base is still too small to smooth out quarterly fluctuations from launch timing and customer inventory decisions.
- The re-energizing plan rests on four levers: New patent-expiry launches, wallet share gains from existing customers, acquisition of new clients, and introduction of distinctive products backed by superior R&D. A pipeline of 15–16 launches is built for the year, dependent on regulator approval timing.
- New DCGI approvals provide near-term ammunition: Several approvals were received this quarter in cardiovascular and diabetes, each carrying four years of shared exclusivity. Sacubitril Valsartan is launching imminently in Q4, with management expecting renewed interest once generic products hit the market given the significant price difference versus the innovator.
- Patent expiry wave supports the medium-term story: Several patent-expiry products in diabetes are coming up through FY23 and FY24, including Linagliptin, Canagliflozin, and Alogliptin.
- Client concentration is manageable: The top customer is below 10% of revenue and the top 10 accounts for 42% on a nine-month basis, dipping below 40% for the quarter.
Hitesh Windlass: "We have to see it more on a YTD basis on an annual basis because from a quarterly perspective, our — while we are at whatever ₹400 crores, it is still too small. And the fluctuations can be there due to some new launches happened, some things got postponed, some multinationals not picking up inventory towards December and various small things."
Trade Generics: The Structural Growth Story
- A distribution model built for India's reality: Only 400–450 towns in India have populations above 1 lakh where the branded-generic, medical-rep model works. Nearly 70% of India lives in 5.5 lakh villages and kasbahs reachable only through a trade generics distribution model, creating a large and defensible opportunity for a quality player.
- Growth has been exceptional and can stay strong: Historical growth rates of 40%, 42%, and 47% will taper as the base grows, but management believes 20–25%+ is sustainable in the long run. The business is on track to approach ₹100 crores this year.
- The competitive set proves the opportunity size: Cipla's trade generics business exceeds ₹1,500 crores, Laborate is also above ₹1,500 crores, and Leeford is nearing ₹1,800 crores. Windlas is a fraction of that scale, leaving a long growth runway.
- Working capital will stay disciplined: Trade generics requires somewhat higher inventory levels, but overall working capital is expected to remain within the 70–85 day range even as the mix shifts toward trade generics and exports.
Hitesh Windlass: "But a huge number of people, almost 70% of India is living in villages and kasbahs, which are more than five and half lakh in number. And you cannot target this market of five and half lakh villages and kasbahs, by putting feet on the ground like a medical rep model. So this is where the whole trade generics space is."
Exports: Early Innings, Regulated-Market Push
- Exports surged 124% YoY this quarter, driven by numerous dossier filings and entry into newer, more regulated markets.
- The market mix is evolving from low-regulation toward regulated: The current concentration is in Southeast Asia and other ROW markets, with small inroads into CIS countries (semi-regulated) and South Africa (regulated). A South Africa approval was announced on the day of the call, with commercialization expected in Q4 or Q1.
- Europe is the next frontier: Plant Four already holds a European GMP certificate. Management is looking at ways to begin supplies to Europe, mindful of price erosion but seeing good opportunities. The company would not rule out putting its own front end in Europe, typically six to seven people, to understand local opportunities and build portfolio strategy.
- Five-year aspiration: Exports are targeted to grow roughly 4x from about ₹20 crores to about ₹80 crores over a four-to-five-year timeframe. Over three to four years, the regional mix is expected to include supplies to Europe, Africa, parts of the Middle East, and Southeast Asia.
Capacity Expansion: Injectables and Beyond
- Injectable facility on track: The facility is scheduled for completion by end of September 2023, with POs already placed and amounts committed. Management expects to finish most work by March 31. The facility is being built keeping PIC/S and European standards in mind.
- Asset turn will take time: A new injectable facility needs a minimum of 1.5 to 2 years to reach the target asset return ratio, given the time required for regulatory approvals and supplies to start across various markets.
- Market mix will shift over four years: Initially, the injectable facility will lean more toward trade generics and CDMO. Toward the end of four years, the mix is expected to tilt more toward exports and less toward CDMO.
- Oral solids capacity is adequate for now: Current utilization is at 42%, with oral solids facilities capable of reaching a maximum of approximately 65%. This provides sufficient capacity for 1 to 1.5 years. To achieve the four-to-five-year aspiration, one more expanded unit will be needed.
- API facility is strategic only: There is no aspiration to expand or enter the API business. The existing pilot facility is used purely for strategic purposes.
Margins, Capital Allocation & Leadership
- Margin improvement despite top-line pressure: EBITDA margins improved to 11.7% from 11.1% YoY, with gross margins up 219 bps YoY. Decreasing input price volatility helped by giving better visibility and enabling improved stocking and purchase decisions.
- Inventory strategy reflects prudence, not distress: Inventory increased because the company has been overstocking some materials to manage input price fluctuations. No specific inventory losses were taken, and regular provisioning continues per accounting practice.
- Buyback underway, dividends also a priority: The board authorized a share buyback of up to ₹25 crores, with 3,87,238 shares repurchased for ₹9.88 crores as of January 25, 2023. Management stated that both buybacks and dividends are very important and seen as a way to reward all shareholders. The company is generating strong operating cash.
- CEO appointment frees up promoter bandwidth: Komal Gupta, formerly CFO for six to seven years, was appointed as CEO. The move is intended to free up Hitesh and Manoj Windlass to focus more on clients. She continues as interim CFO until a new CFO is recruited, a process expected to take three to four months.
- Inorganic discipline demonstrated: The company evaluated a fairly large CDMO player for Europe and Canada markets last quarter but walked away after finding adverse information in quality audits. Future inorganic evaluation areas include market authorization acquisitions in exports and dosage-form expansion into ointments, protein powders, steroids, and hormones.
Hitesh Windlass: "I do want to mention that for us, buybacks and dividends are both very, very important. And we see them as a way in which we can reward all shareholders."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable facility completion | Facility build-out to finish; POs placed, amounts committed | End of September 2023; most work by March 31, 2023 |
| Sacubitril Valsartan launch | Generic launch in Indian market | Q4 FY23 (current quarter); shipment expected imminently |
| South Africa commercialization | Recently approved product to begin supplies | Q4 FY23, or if not, Q1 FY24 |
| Exports growth aspiration | 4x growth from ~₹20 crores to ~₹80 crores | Four to five years |
| CDMO growth | Double-digit CAGR; "significant improvement" from current levels | Three to four years |
| Oral solids capacity expansion | One more expanded unit needed to meet aspiration | Beyond 1–1.5 years (current capacity sufficient for that period) |
| Injectable facility asset returns | Reach target asset return ratio | 1.5 to 2 years minimum from completion |
| Injectable market mix shift | Tilt toward exports, away from CDMO | Toward end of four years from now |
| Working capital range | Maintain within 70–85 days | Ongoing, even as export and trade generics mix increases |
| CFO recruitment | New CFO appointed | Three to four months |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated revenue | ₹119.7 cr, up 2% YoY |
| Consolidated EBITDA | ₹13.9 cr, up 7% YoY |
| Consolidated PAT | ₹9.2 cr, up 11% YoY |
| EBITDA margin | 11.7%, up from 11.1% YoY |
| Gross margin | 219 bps higher YoY |
| CDMO revenue | ₹85.9 cr, down 10% YoY; contributed 72% of consolidated revenue |
| Trade generics revenue | ₹24 cr, up 42% YoY; contributed 20% of consolidated revenue |
| Exports revenue | ₹8.4 cr, up 124% YoY; contributed 7% of consolidated revenue |
| Complex generics share | ~74% of revenue |
| Capacity utilization | 42.3% |
| Top 10 client concentration | Less than 40% of revenue |
| Top customer concentration | Below 10% of revenue |
| Working capital | ~80–82 days, expected to remain within 70–85 days |
| Share buyback completed | ₹9.88 cr (3,87,238 shares) of ₹25 cr authorized, as of 25 Jan 2023 |